Reviewer's report

Title: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

Version: 2 Date: 12 July 2007

Reviewer: Jonathan Rosenberg

Reviewer's report:

General
Accept as revised.

------------------------------------------------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

------------------------------------------------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

------------------------------------------------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

------------------------------------------------------------------------------------------------------------------------

What next?: Accept without revision

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I declare that i have no competing interests.